Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Jazz Pharmaceuticals in a ...

The cannabis-derived compound cannabidiol (CBD) is gaining traction as a treatment for a broad range of conditions, but it's ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought investors’ attention to the company’s appetite in dealmaking.

After bursting onto the scene several years ago with considerable fanfare, much of the hype about cannabis stocks has quietly died down, and ...

GW contributed $991 million to Jazz's overall 2024 revenue, largely driven by its leading product, Epidiolex. This drug is a cannabidiol for the treatment of severe, rare forms of epilepsy.

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have received a consensus rating of “Moderate Buy” from ...

Jazz Pharmaceuticals, a Zacks Rank #1 (Strong Buy), is a specialty biopharmaceutical company that identifies, develops, and ...

The price you pay for Epidiolex may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Chicago, IL – March 12, 2025 – Zacks Equity Research shares Jazz Pharmaceuticals JAZZ as the Bull of the Day and The Boston Beer Company SAM as the Bear ...

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe this is a good deal for Jazz.